Portal de investigación
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ghobrial, Irene M.
- Rodriguez-Otero, Paula
- Koh, Youngil
- Martinez-Lopez, Joaquin
- Parmar, Gurdeep
- Prince, Miles
- Quach, Hang
- Hermansen, Emil
- Hungria, Vania
- Besisik, Sevgi Kalayoglu
- Kim, Jin Seok
- Leleu, Xavier
- Peceliunas, Valdas
- Schjesvold, Fredrik
- Dubin, Franck
- Devisme, Christine
- Lepine, Lucie
- Mace, Sandrine
- Oprea, Corina
- Mateos, Maria-Victoria
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 2152-2650, 2152-2669
- Tipo:
- Correction
- Páginas:
- 545-545
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,778 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical Lymphoma Myeloma & Leukemia CIG MEDIA GROUP, LP
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- erratum
Campos de Estudio
Cita
Ghobrial IM,Rodriguez P,Koh Y,Martinez J,Parmar G,Prince M,Quach H,Rubia JL,Hermansen E,Hungria V,Besisik SK,Kim JS,Leleu X,Peceliunas V,Schjesvold F,Dubin F,Devisme C,Lepine L,Mace S,Oprea C,Mateos M. P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021). Clin. Lymphoma Myeloma Leukemia. 2022. 22(7):p. 545-545. IF:2,700. (3).